Polpharma Pharmaceutical Works - API Manufacturer

Cooperation agreement with the Syncom company

The Fine Chemicals Business Unit of Polpharma and Syncom (the Netherlands) signed a series of agreements to use biocatalysis for the synthesis of chiral intermediates and chiral APIs.

The Fine Chemicals Business Unit of Polpharma, which is the leading Polish generic-pharmaceutical company, and Syncom (the Netherlands) signed, a series of agreements to use biocatalysis for the synthesis of chiral intermediates and chiral APIs. Polpharma believes it is well equipped effectively to compete in this area, by using the expertise of partners like such as Syncom. Syncom is specialized in the area of Organic Synthesis with an emphasis in Chiral Chemistry.

Theo Iliopoulos Vice President of Polpharma and General Manager of Fine Chemicals, said: "Polpharma is uniquely positioned for success in the synthesis of APIs by using innovative technologies, in which the cooperation with Syncom enhances our potentials in delivering cost competitive and environmentally friendly processes as well as in reducing the time to market that are all key differentiating factors in our success."

"Innovation in development methodologies through cooperation and a network of creative forces, is the way forward" he added.

Dr. Ton Vries, CEO of Syncom said: "Syncom is delighted with this opportunity to work with Polpharma. Syncom has always been heavily involved in all aspects of chiral chemistry including biocatalysis and, therefore, we look forward to this opportunity in order to use our knowledge and expertise in this exciting collaboration."